Prophylactic Treatment Pattern Among the Patient’s Diagnosed with Migraine – An Overview
Corresponding Author(s) : Leena Muppa
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 9 No. 3 (2021): 2021 Volume - 9 Issue - 3
Abstract
Background: Migraine is a paroxysmal headache disorder that are characterized by an unilateral p91ain on the head which usually begins at puberty and are much common between 35 to 45 years. The major objective of this review study is to assess the prophylactic treatment pattern among the patients diagnosed with migraine and to provide healthcare professionals with the updated guidance in the use of novel preventive therapy for migraine.
Methods: In this systemic review, we identified 89 articles, among which 40 articles was selected, we rejected articles which are not relevant to the study. Search was conducted with no date limits, Abstracts were first selected for full text review and the results were screened for relevance to the review topic.
Results: Patients with migraine require prophylactic therapy to reduce the frequency of migraine attacks. Currently available evidence-based prophylactic treatment options for migraine are topiramate, propranolol and, sumatriptan was the predominant triptan used for acute treatment. New biologics have been developed to target a specific substance in the brain calcitonin gene-related peptide, which plays a key role in migraine pathophysiology recently, 3 new calcitonin gene-related peptide (CGRP) receptor antagonists-erenumab, fremanezumab, and galcanezumab were approved by FDA for prophylactic treatment of migraine.
Conclusion: Migraine is the most common neurological disorders. The effective and well tolerated new treatment indicated for prophylaxis may also help for prevention of migraine. A pooled analysis of clinical trial result suggests that, migraine prophylaxis may help to prevent migraine severity, migraine, frequency, migraine chronification, and improve quality of life.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
-
[1]. Kathleen B. Digre, The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice, American Headache Society2019;59:1-18.doi: 10.1111/head.13456.
[2]. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24(Suppl 1):9–160.
[3]. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007; 47:355–63.
[4]. Levin – Morris Introduction to ICHD3 [Internet] Available https://americanheadachesociety.org/wp-content/uploads/2018/10/1-.pdf
[5]. Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008; 33(7):404-416.
[6]. Lipton, R.B. and Silberstein, S.D. (2015), Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache: The Journal of Head and Face Pain, 55: 103-122. https://doi.org/10.1111/head.12505_2
[7]. Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet Neurology. 2018 Feb 1;17(2):174-82.
[8]. Sharon Scott Morey, Guidelines on Migraine: Part 4. General Principles of Preventive Therapy, Am Fam Physician. 2000 Nov 15;62(10):2359-2362..
[9]. Canadian 1. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012 Mar;39(2 Suppl 2):S1-59.
[10]. CannadianHeadchesociety[internet]availablefrom https://www.guidelinecentral.com/summaries/canadian-headache-society-guideline-for migraine-prophylaxis/#section-society
[11]. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan. 59 (1):1- 18. Brauser D. AHS Releases Updated Guidance on Migraine Treatment. Medscape Medical News. Available at https://www.medscape.com/viewarticle/907493. 2019 Jan 10; Accessed:January 31, 2019.
[12]. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813–818.
[13]. Silberstein SD, Freitag FG, Gilbert T T, Frishberg BM, et al. U.S. Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Copyright © by the American Academy of Neurology.
References
[2]. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24(Suppl 1):9–160.
[3]. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007; 47:355–63.
[4]. Levin – Morris Introduction to ICHD3 [Internet] Available https://americanheadachesociety.org/wp-content/uploads/2018/10/1-.pdf
[5]. Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008; 33(7):404-416.
[6]. Lipton, R.B. and Silberstein, S.D. (2015), Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache: The Journal of Head and Face Pain, 55: 103-122. https://doi.org/10.1111/head.12505_2
[7]. Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet Neurology. 2018 Feb 1;17(2):174-82.
[8]. Sharon Scott Morey, Guidelines on Migraine: Part 4. General Principles of Preventive Therapy, Am Fam Physician. 2000 Nov 15;62(10):2359-2362..
[9]. Canadian 1. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012 Mar;39(2 Suppl 2):S1-59.
[10]. CannadianHeadchesociety[internet]availablefrom https://www.guidelinecentral.com/summaries/canadian-headache-society-guideline-for migraine-prophylaxis/#section-society
[11]. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan. 59 (1):1- 18. Brauser D. AHS Releases Updated Guidance on Migraine Treatment. Medscape Medical News. Available at https://www.medscape.com/viewarticle/907493. 2019 Jan 10; Accessed:January 31, 2019.
[12]. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813–818.
[13]. Silberstein SD, Freitag FG, Gilbert T T, Frishberg BM, et al. U.S. Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Copyright © by the American Academy of Neurology.